Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,083 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lymphoid Clear all
Withdrawn Phase 2 Interventional

Lenalidomide and Obinutuzumab for Previously Untreated CLL

NCT02371590
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Obinutuzumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Nov 13, 2026, 1:05 PM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

NCT05038384
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1Phase 2 Interventional

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

NCT01702155
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Interventions
DFP-10917
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Nov 13, 2026, 1:05 PM EST
Terminated Not applicable Interventional Results available

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

NCT00608517
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Nov 13, 2026, 1:05 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925
View directory record Official record
Conditions
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1 Interventional

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

NCT00217412
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, isotretinoin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Nov 13, 2026, 1:05 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study

NCT05772130
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Hereditary Malignant Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Electronic Health Record Review, Personal Contact, Survey Administration
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Terminated Phase 3 Interventional Results available

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02013167
View directory record Official record
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Standard of Care Chemotherapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Nov 13, 2026, 1:05 PM EST
Recruiting Phase 2 Interventional

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1 Interventional

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

NCT00098436
View directory record Official record
Conditions
Leukemia
Interventions
laromustine, temozolomide
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Indianapolis, Indiana • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1 Interventional

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00012207
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide, prednisone, vincristine sulfate, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
3
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 2 Interventional Results available

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

NCT01185171
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD 1839 500mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1 Interventional

Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

NCT00908167
View directory record Official record
Conditions
Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, Biphenotypic Leukemia
Interventions
Sorafenib, Cytarabine, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 31 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Nov 13, 2026, 1:05 PM EST
Active, not recruiting No phase listed Observational

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

NCT04537871
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions
Bioelectric Impedance Analysis, Biospecimen Collection, Cardiopulmonary Exercise Testing, Echocardiography, Physical Performance Testing, Pulmonary Function Test, Questionnaire Administration, Ultrasound
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Terminated Phase 2 Interventional Results available

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

NCT02258529
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions
Idelalisib, Rituximab
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Long Beach, California • Fort Myers, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1 Interventional

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

NCT00351975
View directory record Official record
Conditions
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Belinostat, Azacitidine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Nov 13, 2026, 1:05 PM EST
Recruiting No phase listed Observational

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

NCT05865301
View directory record Official record
Conditions
Lymphoid Leukemia
Interventions
Questionnaire for patients receiving therapy
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 26 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Recruiting No phase listed Observational

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

NCT05014165
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cord blood Sample Collection, Case identification and recruitment, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 1 Interventional

T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL

NCT00709033
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
autologous or syngeneic PBTLs and EBV-CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Nov 13, 2026, 1:05 PM EST
Terminated Phase 1 Interventional

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

NCT00672152
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), B Cell Malignancies
Interventions
WT1 derived peptides
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Nov 13, 2026, 1:05 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge

NCT03369847
View directory record Official record
Conditions
Asthma, Pediatric ALL
Interventions
budesonide, beclomethasone
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
Up to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Nov 13, 2026, 1:05 PM EST
Terminated Phase 1 Interventional

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
XL114
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Nov 13, 2026, 1:05 PM EST